Elevated serum levels of high mobility group box protein 1 (HMGB1) in patients with ankylosing spondylitis and its association with disease activity and quality of life

Basit Öğe Kaydı
dc.contributor.authorOktayoglu, Pelin
dc.contributor.authorEm, Serda
dc.contributor.authorTahtasiz, Mehmet
dc.contributor.authorBozkurt, Mehtap
dc.contributor.authorUcar, Demet
dc.contributor.authorYazmalar, Levent
dc.contributor.authorNas, Kemal
dc.date.accessioned2024-04-24T16:00:05Z
dc.date.available2024-04-24T16:00:05Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractThis study was carried out to determine the serum levels of high mobility group box protein 1 (HMGB1) in patients with ankylosing spondylitis (AS) and to evaluate its correlation with disease activity and quality of life. According to our knowledge, it is the first trial evaluating HMGB1 levels in AS. Serum samples of 30 patients (18 males and 12 females) with AS and 29 healthy controls (HC) (15 females and 14 males) were collected. HMGB1 levels were measured by enzyme-linked immunosorbent assay, activity of disease was assessed according to the Bath AS Disease Activity Index (BASDAI), and functional status of patients was evaluated with Bath AS Functional Index (BASFI). Modified Schober, chest expansion values and AS Quality of Life Questionnaire (ASQoL) scores were noted. The serum levels of HMGB1 were obtained significantly increased in AS patients compared to HC (p < 0.05). There was no significant correlation between HMGB1 levels and ESR (p > 0.05), and CRP (p > 0.05) values. BASDAI, BASFI and ASQoL scores were also not correlated with serum levels of HMGB1 (p > 0.05). Our results suggest that HMGB1 might play an important role in the pathogenesis of AS; however, it seems not to be a good candidate for reflecting disease activity, functional abilities and the quality of life in patients with AS; on the other hand, the increased levels of HMGB1 in patients may open a new dimension for targeting this cytokine as a new therapy option in AS.en_US
dc.identifier.doi10.1007/s00296-012-2578-y
dc.identifier.endpage1331en_US
dc.identifier.issn0172-8172
dc.identifier.issn1437-160X
dc.identifier.issue5en_US
dc.identifier.pmid23143556
dc.identifier.scopus2-s2.0-84878017388
dc.identifier.scopusqualityQ1
dc.identifier.startpage1327en_US
dc.identifier.urihttps://doi.org/10.1007/s00296-012-2578-y
dc.identifier.urihttps://hdl.handle.net/11468/14366
dc.identifier.volume33en_US
dc.identifier.wosWOS:000318172400032
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.ispartofRheumatology International
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAnkylosing Spondylitisen_US
dc.subjectHigh Mobility Group Box Protein 1en_US
dc.subjectDisease Activityen_US
dc.subjectQuality Of Lifeen_US
dc.titleElevated serum levels of high mobility group box protein 1 (HMGB1) in patients with ankylosing spondylitis and its association with disease activity and quality of lifeen_US
dc.titleElevated serum levels of high mobility group box protein 1 (HMGB1) in patients with ankylosing spondylitis and its association with disease activity and quality of life
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu